Brexit uncertainty favours internationally focused pharmaceutical professionals
![](/46/pdcnewsitem/04/16/98/nonstop%20recruitment.png)
Its likely that a number of firms will relocate their services to mainland Europe or Ireland.
The uncertainty over the state of the pharmaceutical industry following Brexit will favour internationally focused professionals, according to NonStop Recruitment.
With the UK deciding to leave the EU last month, a number of commentators have suggested that the sector will face ‘immediate challenges’ including the regulation of medicine, funding research and the potential relocation of The European Medicines Agency. NonStop has warned that professionals with internationally focused skill sets, such as foreign languages and wider commercial experience, are likely to be the ones to benefit from this new landscape.
Matt Beedle, Team Leader within NonStop Pharma, comments: “While we obviously can’t be certain about the future of the market, it seems highly likely that a number of firms will relocate their services to mainland Europe or Ireland, probably to match the relocation of The European Medicines Agency, which is the reason many companies base their operations in London in the first place. This means that these firms will have to move their staff and not everyone is well suited to a role working on foreign shores, for a variety of reasons. Consequently, from our analysis we believe that professionals with an internationally focused skill set are likely to have the best prospects in this new climate.”
“The full extent of the UK’s decision to leave the single market will remain to be seen, but it’s also likely that we’ll face added challenges with both funding cuts and firms no longer having access to EU grants. However, these are longer term issues and in the short term it’s likely that pharmaceutical professionals will be concerned over their job security. The market is so tumultuous at the moment that it’s hard to make an accurate prediction for the future, but we believe that those individuals who can highlight their internationally focused attributes and experience will prosper.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance